Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,372,995

« Back to Dashboard

Which drugs does patent 8,372,995 protect, and when does it expire?


Patent 8,372,995 protects TYGACIL and is included in one NDA. There has been one Paragraph IV challenge on Tygacil. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has twenty-five patent family members in twenty-six countries.

Summary for Patent: 8,372,995

Title:Crystalline solid forms of tigecycline and methods of preparing same
Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
Inventor(s): Krishnan; Lalitha (Suffern, NY), Deshmukh; Subodh S. (White Plains, NY), Hadfield; Anthony (St. Petersburg, FL), Huang; W. James (Hillsborough, NJ), Ku; Mannching Sherry (Thiells, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:11/440,032
Patent Claim Types:
see list of patent claims
Composition; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
TYGACIL
tigecycline
POWDER;IV (INFUSION)021821-001Jun 15, 2005APRXYesYes8,372,995► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,372,995

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2007143160► Subscribe
Portugal1890996► Subscribe
Norway20076005► Subscribe
Peru00242007► Subscribe
Mexico2007014735► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot